WO2023214437 - SYSTEM AND METHOD OF DELIVERING INHIBITORS FOR PREVENTING THE ENTRY OF SARS-CoV-2 AND EMERGING VARIANTS
National phase entry is expected:
Publication Number
WO/2023/214437
Publication Date
09.11.2023
International Application No.
PCT/IN2023/050437
International Filing Date
05.05.2023
Title **
[English]
SYSTEM AND METHOD OF DELIVERING INHIBITORS FOR PREVENTING THE ENTRY OF SARS-CoV-2 AND EMERGING VARIANTS
[French]
SYSTÈME ET MÉTHODE D'ADMINISTRATION D'INHIBITEURS POUR EMPÊCHER L'ENTRÉE DU SARS-COV-2 ET DE VARIANTS ÉMERGENTS
Applicants **
BORDOLOI, Binoy K.
Bordoloi Nagar, Kushal Kanwar Path, Jail Road, Assam
Jorhat 785001, IN
Inventors
SAINI, Kulwant S.
WS 144, Woodstock, Nirvana Country, Sector-50, Haryana
Gurugram 122018, IN
KUMAR, Sachin
D63 IIT Guwahati Campus, Assam
Guwahati 781039, IN
MAZUMDER, Priyanka
Block A-8/133, P.O Kalyani, West Bengal
Nadia 741235, IN
Priority Data
202231026507
06.05.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP India
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter II
* |
| * | |
| * | |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1055 | |
| EPO | Filing, Examination | 4980 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2710 |
Total: 9909 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention discloses a composition and method for treating viral infections. The composition and method deliver inhibitors for preventing the entry of SARS-Cov-2 viral infections and the emerging variants are disclosed. The composition comprises a protease inhibitor comprising calcium salt of Tranexamic acid (Ca-TA). The protease inhibitor further comprises lithium salt of Tranexamic acid (Li-TA). The composition demonstrates efficacy in fibrin clot systems, where the Ca salt shows unexpected behavior of clot swelling, unlike TA. This inhibitor blocks the peptide or enzyme known as plasmin from interacting with fibrin (a protein) and subsequently breaking it down. TA is a safe and commonly used small molecule drug. The Ca-TA inhibitor interferes with the binding of the viral spike protein of SARS-CoV-2 to the human cell surface receptor angiotensin- converting enzyme-2 (ACE-2) to avoid infections caused by SARS-CoV-2 infections and emerging variants.[French]
La présente invention divulgue une composition et une méthode de traitement d'infections virales. La composition et la méthode fournissent des inhibiteurs pour prévenir l'entrée d'infections virales du SARS-CoV-2 et les variants émergents. La composition comprend un inhibiteur de protéase comprenant un sel de calcium d'acide tranexamique (Ca-TA). L'inhibiteur de protéase comprend en outre un sel de lithium d'acide tranexamique (Li-TA). La composition démontre une efficacité dans des systèmes de caillot de fibrine, le sel de Ca présentant un comportement inattendu de gonflement de caillot, contrairement au TA. Le présent inhibiteur bloque l'interaction du peptide ou de l'enzyme, connu sous le nom de plasmine, avec la fibrine (une protéine) et sa décomposition ultérieurement. Le TA est un médicament à petites molécules sûr et couramment utilisé. L'inhibiteur de Ca-TA interfère avec la liaison de la protéine de spicule virale du SARS-CoV-2 à l'enzyme 2 de conversion d'angiotensine de récepteur de surface de cellule humaine (ACE-2) pour éviter des infections provoquées par des infections par le SARS-CoV-2 et des variants émergents.